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ORAL PRESENTATIONS
O1
Multidetector CT Improving Surgical Outcomes in Breast Cancer (MISO BC).
J Cox1*, H Hancock2, J Spratt1, H Close2, CM Lee1, U Mohammed2, J Mason2
1County Durham and Darlington NHS Foundation Trust, Durham, UK.;
2Durham University, Durham, UK.
Breast Cancer Research 2014, 16(Suppl 1):O1
Introduction: This multicentre randomised controlled trial investigated
whether a computed tomography (CT) scan of the axilla could more
accurately assess whether the axillary lymph nodes were involved with
malignancy in patients with newly diagnosed breast cancer and therefore
influence surgical decision-making with regard to axillary surgery.
Methods: Patients with newly diagnosed breast cancer (via screening and
symptomatic routes) at two NHS Trusts in the North East of England were
recruited and randomised in equal numbers. Both groups received routine
diagnostic and surgical care (usual care). In addition, one group received a
CT scan of their axilla on the same side as the breast cancer.
Results: The study recruited 297 patients, of whom 291 contributed to
findings. CT scan-guided care did not result in a change in the need for a
second operation, with about 20% of both groups needing further surgery.
Patients within the two groups were similar before treatment, had similar
types and grade of cancer, experienced similar pattern complications and
reported similar experiences of care.
Conclusion: New diagnostic imaging technologies regularly enter NHS
centres of excellence as research tools. It is important these are evaluated
rigorously before becoming routine care. In patients newly diagnosed with
breast cancer, CT-augmented diagnosis of cancer in the axilla was not found
to improve surgical outcomes or patient experience.
O2
Preoperative assessment of breast volume to aid surgical planning:
comparison of software-based mammographic measurements with
subsequent mastectomy volumes.
I Teo1*, P Whelehan1,2, EJ Macaskill1,2, D Alex Munnoch1,2, S Vinnicombe1,2,
Andy Evans1,2
1NHS Tayside, Dundee, UK.; 2University of Dundee, UK.
Breast Cancer Research 2014, 16(Suppl 1):O2
Introduction: The proportion of breast volume excised during conservation
surgery for breast cancer is crucial to cosmetic outcomes. Validated,
expedient methods for accurate preoperative quantification of breast
volume are lacking. This study evaluated breast volume measurements
calculated by Volpara® breast density software, by comparing them with
actual mastectomy volumes.
Methods: From a prospective clinical database, 31 patients were identified
for whom Volpara® (Matakina Technology Limited, New Zealand) volume
measurements and mastectomy volumes were available. All patients had
undergone skin-sparing mastectomy (SSM), bilateral in one case. Specimen
volumes had been measured using a water-displacement technique.
Volpara® volumes for the corresponding CC and MLO view of each of the
32 breasts were averaged and compared with the mastectomy volumes.
Correlation was assessed using the Pearson correlation coefficient.
Results: Volpara® breast volumes were, as expected, consistently higher
than SSM volumes but with a very strong correlation (Pearson correlation
coefficient for average Volpara® volumes and mastectomy volumes = 0.82
(P < 0.01)).
Conclusion: The excellent correlation between Volpara® and SSM volumes
suggests that this readily available and convenient preoperative measure
of breast volume could be used as a tool to aid surgical planning in
women with breast cancer, which might be particularly useful in those
women not scheduled for preoperative MRI. When coupled with accurate
measurement of tumour size plus required excision margin volume,
possibly from three-dimensional ultrasound, this tool could potentially
outperform current subjective preoperative methods of assessing relative
volumes. Further validation work is needed.
O3
Efficacy of second-time vacuum-assisted breast excision in the
management of screen-detected high-risk breast lesions.
M Morgan1,2*, R Patel1,2, W Teh1,2
1Northwick Park Hospital, Harrow, UK.; 2North London Breast Screening,
London, UK.
Breast Cancer Research 2014, 16(Suppl 1):O3
Introduction: Surgical excision of breast lesions is usually required for
high-risk (B3) lesions or radiological pathological discordance. The risk of
underestimation of malignancy is 45 to 50% for 14G core biopsy and
20 to 25% for vacuum-assisted biopsies (VAB).
Methods: In our institution, all screen-detected microcalcifications or
ultrasound occult lesions are subjected to 11G VAB. If a discordant or
high-risk lesion (B3) - for example, atypical ductal hyperplasia (ADH),
lobular neoplasia or papillary lesion - is diagnosed on the initial VAB, an
8G vacuum-assisted breast excision (VAE) may be performed following
MDT discussion.
Results: Between 2011 and 2013, 1,250 VAB were performed on 990
women. Eighty-three 8G VAEs were performed during this time, and of
these 62.7% of lesions (52/83) were classified histologically as B2, 24.1%
(20/83) remained B3, 2.4% (2/83) as B4, 7.2% (6/83) as B5a and 2.4% (2/83)
as B5b. Following 8G VAE, 45 patients (54.2%) were discharged to
screening, six patients (7.2%) underwent annual surveillance, diagnostic
surgery was performed on 23 patients (27.7%) and therapeutic surgery on
eight patients (9.6%).
Conclusion: Our study demonstrates that 8G VAE after an initial B3
diagnosis on VAB can avoid diagnostic surgery and improve cancer
detection. Surgery was not required in 51 of the 83 cases (61.4%) of B3
Breast Cancer Research 2014, Volume 16 Suppl 1
http://breast-cancer-research.com/supplements/16/S1
© 2014 various authors, licensee BioMed Central Ltd. All articles published in this supplement are distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
lesions found on initial 11G VAB. A total of 17 B3 lesions (20.5%) were
upgraded after 8G VAE; nine by diagnostic surgery (12%) and eight of the
83 cases of B3 lesions (9.6%) by VAE to either B5a or B5b requiring
definitive surgery. Lesions most likely to be upgraded to malignancy were
lobular neoplasia and ADH.
O4
Local breast density at lesion sites in diagnostic and previous
screening mammograms.
M Otsuka1*, E Harkness2,3, X Chen2, E Moschidis2, M Bydder3, S Gadde3,
Y Lim2,3, A Maxwell2,3, DG Evans3,4, A Howell3,4, P Stavrinos3,5, M Wilson3,
S Astley2,4
1University of Manchester Medical School, Manchester, UK.; 2Centre for Imaging
Sciences, Institute of Population Health, University of Manchester, UK.;
3Nightingale Centre and Genesis Prevention Centre, University Hospital of
South Manchester, Manchester, UK.; 4Manchester Breast Centre, Manchester
Cancer Research Centre, University of Manchester, UK.; 5The University of
Manchester, Manchester Academic Health Science Centre, University Hospital of
South Manchester NHS Foundation Trust, Manchester, UK.
Breast Cancer Research 2014, 16(Suppl 1):O4
Introduction: High overall breast density is associated with increased risk of
developing cancer. Semi-automated analysis of digitised analogue
mammograms has previously suggested that local increases in density may
occur prior to cancers being detected. We investigate local density at the
site of cancers in diagnostic and previous full-field digital screening
mammograms using quantitative measures.
Methods: Volpara® volumetric breast density maps were obtained for 54
mammograms in which unilateral breast cancer was detected, and the
corresponding previous digital screening mammograms that had been read
as normal. A 5 mm square region was sampled from CC-view density maps
at the lesion site in both diagnostic and previous screening mammograms,
and in corresponding locations on the opposite side. Local percent density
was computed.
Results: In previous screening mammograms, local breast density was
significantly increased at the future lesion site compared with a similar
location in the opposite breast (medians 18.82%, 9.45%, P < 0.001). Breast
density at the lesion site in diagnostic mammograms was higher than
that of a corresponding area in the opposite breast (medians 21.58%,
9.18%, P < 0.001). It was also greater than the density of the same
location in the previous screening mammogram (P = 0.012).
Conclusion: Local breast density is increased at sites where cancer will
develop in the future compared with corresponding regions in the opposite
breast. Cancer sites in diagnostic images have greater density than the same
region in previous screening mammograms and corresponding contralateral
regions. Detection of localised increases in breast density could enhance
computer-aided detection of early breast cancer.
O5
Are abnormalities missed in the PERFORMS self-assessment scheme
due to visual or cognitive factors?.
Y Chen*, L Dong, A Gale
Loughborough University, Loughborough, UK.
Breast Cancer Research 2014, 16(Suppl 1):O5
Introduction: To examine whether missed abnormalities in PERFORMS test
sets are mainly due to visual or cognitive factors.
Methods: Data were examined from three recent rounds of the PERFORMS
breast screening self-assessment scheme (that is, three sets of 120 difficult
normal, benign and malignant FFDM cases) that had respectively been
reported by 723, 726 and 687 breast radiologists and advanced practitioners
in order to determine the error rates and the underlying reasons for such
errors. Every participant had read each case set in a different random order.
Results: The cancer detection in the three rounds was high, with mean
values of 82%, 86% and 93%. However, in terms of discrepant recall
decisions between individuals and overall decisions, there were both over-
reading (for the normal and benign cases) and under-reading errors (for the
malignant cases) for many cases; although there was no statistical difference
in the error rate between these three case categories. Overall, for the normal
cases there were 15.55% false positives, with the majority of these being
scored as indeterminate (13.37%). For malignant cases there were 16% false
negatives, with 11.45% reported normal and 4.12% benign. Further analyses
demonstrated that the majority of the false negative errors were due to
mammographic features being missed (unseen) rather than being seen but
then misinterpreted - a cognitive error (t test, P < 0.002).
Conclusion: In examining these difficult case sets from the PERFORMS
scheme, most errors were due to key abnormal mammographic features
not being seen.
O6
Digital breast tomosynthesis improves the accuracy of the diagnosis of
circumscribed lesions because of increase of margin visibility.
R Wasan*, J Morel, A Iqbal, D Evans, J Goligher, C Peacock, R Rahim,
K Satchithananda, M Michell
King’s College Hospital, London, UK.
Breast Cancer Research 2014, 16(Suppl 1):O6
Introduction: Circumscribed masses are a common cause of recall for
assessment but most are benign. The aim of this study is to compare the
accuracy of digital breast tomosynthesis (DBT) with digital mammography
(DM) in assessing the margin of circumscribed lesions as a predictor of
benign or malignant disease.
Methods: The study group consisted of women recalled from breast
screening for further assessment of circumscribed masses. Clients
underwent co-registered DM and DBT in both MLO and CC projections. Two
experienced breast radiologists evaluated DM and DBT images and a
consensus decision was reached on the percentage of the margin that was
well defined on DM and DBT. The lesions were categorised 1 to 4 as follows:
1 = 0 to 25%, 2 = 26 to 50%, 3 = 51 to 75% and 4 = 76 to 100%.
Results: One hundred and twenty circumscribed lesions were evaluated.
Data on 118 lesions seen on the MLO view are presented. There were 93
benign lesions and 25 cancers. There was a change in distribution of margin
categories between DM and DBT. More lesions were categorised as 3 or 4
on DBT (59/118) compared with DM (18/118). Of the 93 benign lesions, 17
were categorised as 3 or 4 on DM and 57 on DBT. The difference between
the two proportions was significant (P < 0.0002). There were more cancers
categorised as 1 on DBT (21/39 = 54%) compared with DM (20/76 = 26%);
Fisher’s exact test (P < 0.004).
Conclusion: Increased margin visibility of circumscribed masses by DBT
improves the accuracy of mammography interpretation and may
decrease the recall rate in mammography screening.
POSTER PRESENTATIONS
P1
PB.34. Marker clip placement may not be needed in breast cancer
patients undergoing neoadjuvant chemotherapy with a view to
breast-conserving surgery whose tumours are associated with
microcalcification.
M Sreenivas
UHCW Hospitals NHS Trust, Coventry, UK.
Breast Cancer Research 2014, 16(Suppl 1):P1
Introduction: Patients who are potential candidates for breast conservation
surgery following neoadjuvant chemotherapy have their tumours marked
with a maker clip to guide surgery. Some of the breast cancers are
associated with microcalcification. So far we have not seen any publication
showing the potential use of tumour-associated microcalcification, which
could be used as marker of the tumour bed instead of a marker clip. We
present prospective case series where microcalcification associated with
tumour had been used to guide surgery.
Methods: Thirty-eight patients with breast cancers underwent neoadjuvant
chemotherapy between 1 December 2012 and 7 May 2014 at a single
institute. At the end of chemotherapy 16 patients underwent successful
breast-conserving surgery (BCS). Nineteen patients’ tumours were associated
with microcalcification.
Results: Of the patients who underwent successful BCS, seven had tumour-
associated microcalcification. In six of these patients the tumour-associated
microcalcification was solely used as a marker of the tumour bed. In one
case, due to the presence of few tiny eccentric specks of microcalcification
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associated with the tumour, it was decided to place a maker clip. In all seven
cases, tumour-associated microcalcification was readily apparent during
localisation.
Conclusion: Traditionally, placement of commercially available markers
clips (costs around £55 per clip) is recommended for patients considered
suitable for BCS following neoadjuvant chemotherapy. Albeit a small series,
our experience demonstrates that tumour-associated microcalcification will
still be apparent after completion of neoadjuvant chemotherapy and as
such can be used as a marker of the tumour bed, thus saving costs
associated with clip placement.
P3
PB.12. Audit and root-cause analysis of classification 2 and 3 interval
cancers.
D Cox*, A Powell
Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, UK.
Breast Cancer Research 2014, 16(Suppl 1):P3
Introduction: The definition of an interval cancer is a cancer diagnosed
between scheduled screening rounds. Interval cancer rates are an
indication of the effectiveness of a Breast Screening Service in achieving
early cancer detection, thus reducing overall mortality secondary to breast
cancer, and represent a National Health Service Breast Screening
Programme (NHSBSP) standard. The British Society of Breast Radiology
(BSBR) Interval Classifications are as follows: 0 = unclassifiable, 1 = normal/
benign, 2 = uncertain and 3 = suspicious. An audit was undertaken of
interval cancers assigned a classification of 2 or 3 within our Breast Service
over a 3-year period with the aim of determining and implementing
improved clinical practice in a learning environment.
Methods: The screening and symptomatic records were collected for all
NHSBSP clients over a 3-year period subsequently diagnosed with a
classification 2 or 3 interval cancer to establish the interval cancer rate
benchmarked against NHSBSP standards and to determine the causal
factors within the screening pathway.
Results: During the audit period 93,296 women underwent breast
screening. The total number of interval cancers was 220. Of these 52 were
assigned a 2 or 3 interval cancer classification. The NHSBSP standard of 1.2
interval cancers per 1000 women screened for the first 2 years following
screening was not achieved for women screened within the initial 2 years of
the audit period.
Conclusion: Causal factors were most commonly associated with double
mammographic screen reading. Subsequent interval cancers occurring most
commonly during an incident screen in women aged 50 to 59 years, 12 to
24 months following NHSBSP screening.
P4
PB.6. Management of radial scars on core biopsy.
L Hodkin*, R Millican-Slater, N Sharma
Leeds Teaching Hospitals Trust, Leeds, UK.
Breast Cancer Research 2014, 16(Suppl 1):P4
Introduction: Radial scar (RS) is a pathological diagnosis which is classified
as B3 indeterminate due to the associated risk of malignancy. Further tissue
sampling is therefore required, which traditionally was with surgical excision.
In Leeds since 2009 we have been managing RS with vacuum-assisted
biopsy, if <15 mm with no atypia; otherwise surgical management is taken.
We reviewed cases since 2009 to identify how RS has been managed and if
this is appropriate.
Methods: From 1 April 2009 to 31 March 2013 all RSs assigned B3 on
histology were identified. The imaging features, size, histology and
subsequent management were documented.
Results: Sixty-four patients were identified, 48 from breast screening and
16 symptomatic. Size of RS ranged from 2 to 70 mm. On imaging, five
presented as asymmetry, one as asymmetry with calcification, 40 stromal
deformities, five stromal deformities with calcification, four masses, eight
calcifications and one normal. Overall, 13 RSs had associated atypia (three
cancers) and 51 with no atypia on biopsy had six associated cancers on
diagnostic surgery (RS >20 mm) - three LCIS and three DCIS. In total, 27/64
had diagnostic surgical biopsy (five had VAB preoperatively) and 37 had
second-line VAB, of which seven are on 5-year FU.
Conclusion: Yield of malignancy for small (<20 mm) RS with no atypia is
low, therefore management with second-line VAB is appropriate rather
than surgical diagnostic biopsy, providing there is radiological and
pathological correlation with representative sampling.
RS with atypia still requires diagnostic excision, with a 23% upgrade to
cancer discovered from our cases.
P6
PB.13. Impact on film reading of moving from analogue to digital
screening: a service evaluation - South East Scotland Breast Screening
Programme.
G Babu*, A Gilchrist, J Murray
NHS Lothian, Edinburgh, UK.
Breast Cancer Research 2014, 16(Suppl 1):P6
Introduction: In 2013 this unit became the first in Scotland to switch from
analogue to digital mammographic screening. This study analyses the
impact of this change on film reading practice with a reflective
questionnaire and comparative analysis of recall, arbitration rates and
positive predictive values (PPV).
Methods: Film readers in this unit are radiologists, radiographers and
clinicians. A questionnaire was designed to assess individual reading
practice before and after the switch to digital screening including
perception of lesion types. We used SBSP reports and internal statistics for
the comparative analysis.
Results and conclusion: Eleven of 13 film readers responded. All readers
agreed they enjoyed digital reading. All readers agreed the ability to
manipulate images was useful. Most readers felt they would have liked more
training when digital mammography was introduced. Eight readers felt
digital was convenient and easier to read. Three felt it took longer. Several
recorded intermittent eye strain. Readers found comparison with previous
analogue films problematic. All readers review their reading figures annually.
Nonradiologists do formalised self-audit, which continues after training. This
tool is less used by radiologists, who obtain informal feedback from clinics
and MDM. Fifty per cent of readers felt that reading guidelines would be
helpful. With digital reading, all were confident reading opacities but
recalling more calcifications. Readers were generally less confident with
asymmetries and parenchymal distortions. Using two comparable 6-month
periods, recall rates showed an initial peaking with introduction of digital
screening. Arbitration rates increased but PPV significantly improved.
P7
PB.14. An analysis of subtle alterations in reading pattern with the
introduction of digital mammography screening: South East Scotland
Breast Screening Programme.
G Babu*, A Gilchrist, J Murray
NHS Lothian, Edinburgh, UK.
Breast Cancer Research 2014, 16(Suppl 1):P7
Introduction: Digital screening was implemented in this programme in
November 2013. Following an impression that the pattern of recalls had
changed, this study aimed to identify cases recalled for subtle or vague
mammographic features which were true lesions and those where there
was overcall, and perhaps suggest guidance for readers.
Methods: A total of 235 recall cases were randomly identified between
November 2013 and March 2014. All were possible subtle lesions,
parenchymal deformity or asymmetry. Definite opacities, calcifications and
symptoms were excluded. The cases were reviewed by two experienced film
readers and a specialist trainee and categorised as Category 1, definite
overcall; Category 2, Possible overcall; category 3, definite recall.
Results and conclusion:
Following assessment, all cases in Category 1 were composite normal
breast tissue (NBT) and returned to normal routine recall. In Category 2, 37
were composite NBT; 19 were real lesions, mostly cysts; four were cancers.
In Category 3, 51 were real lesions, mostly cysts; 17 were cancers. This
study has demonstrated that in Category 1 cases (definite overcall), no
cancers would have been missed. In Category 2 cases (possible overcall),
we must accept some overcall as this group can hide subtle cancers. In
Category 3 cases (definite recall), almost all warranted recall. The cancers
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appeared suspicious on screening mammograms. The difference in feature
perception between digital and analogue mammography is significant and
may alter recall practice. Critical analysis of subtle appearances is required
to prevent overcall for future readers.
P8
PB.41. What is the incidence of internal mammary node
lymphadenopathy on CT in primary breast cancer patients within
1 year of a diagnosis?.
S Savaridas*, J Cox
University Hospital of North Durham, Durham, UK.
Breast Cancer Research 2014, 16(Suppl 1):P8
Introduction: The importance of internal mammary nodes (IMNs) in the
staging and treatment of breast cancer patients is controversial.
Lymphoscintigraphic studies have demonstrated that a significant
proportion of breast cancers have primary or partial IMN drainage. However,
historical studies demonstrated no overall benefit of treating IMNs with
either surgery or radiotherapy. But with recent advances in treatment,
targeted radiotherapy of the IMN chain is now possible. Thus we sought to
establish the frequency of IMNs within our primary breast cancer population.
Methods: Retrospective cohort study of all spiral CT thorax performed on
patients within 12 months following the primary diagnosis of breast
cancer from January 2009 to December 2012. The number and size of
any IMNs were recorded.
Results: A total of 830 patients were diagnosed with primary breast cancer
within our time frame; 150 patients were included in this study. Of these,
40% (n = 60) had IMNs present, although the majority were small (<5 mm).
However, 16% (n = 24) had larger nodes >5 mm present on CT.
Conclusion: We have demonstrated that IMNs are present in a substantial
number of our primary breast cancer patients. We suggest that routine
imaging of the IMN chain as well as axilla should be considered in the
staging of breast cancer.
P9
PB.42. Influences upon presentation to the symptomatic breast clinic:
is there an increase in symptomatic referrals due to the physical
presence of the breast screening van within an area?.
F Wotton1*, R Green2
1Peninsula Radiology Academy, Plymouth, UK.; 2South Devon Healthcare
NHS Foundation Trust, Torquay, UK.
Breast Cancer Research 2014, 16(Suppl 1):P9
Introduction: Current published literature on health-seeking behaviour in
women with a self-detected breast lesion mainly explores the reasons
surrounding why a delayed presentation may occur. However, there is no
current literature on whether the presence of the National Breast Screening
van has any influence on symptomatic referrals. Therefore, the authors
propose there will be an increase in symptomatic referrals within the cohort
of patients who share a postcode with the breast screening van location.
Methods: The National Breast Screening van was parked in the TQ4
postcode between 30 November 2012 and 30 June 2013. All new GP
symptomatic breast referrals between the above dates and those during
the same timeframe of the previous year were recorded by age and
postcode. The referral patterns, ages and number of new symptomatic
breast cancer diagnoses between were compared between the study
timeframes.
Results: There was a 12% increase in overall referrals during the study
timeframes in 2011/12 to 2012/13. There were no significant differences in
referral patterns by postcode. However, there was a statistically significant
increase in referrals in younger patients with a consequent reduction in
those of screening age (P < 0.001), when compared with a separate
postcode. No difference in new symptomatic breast cancer diagnoses was
seen during the two timeframes.
Conclusion: Whilst the presence of the screening van did not influence
overall referrals, there was a shift in age distribution with a statistically
significant increase in younger, prescreening women and a consequent
decrease in older, screening-age women. The screening van did not
influence the number of new symptomatic breast cancers.
P10
PB.26. MRI-guided breast biopsy in Leeds: 12 years’ experience.
S Rajan*, N Sharma, B Dall
Breast Imaging Unit, St James’s University Hospital Trust, Leeds, UK.
Breast Cancer Research 2014, 16(Suppl 1):P10
Introduction: MRI-guided biopsy allows sampling of lesions occult on
conventional imaging to reach a preoperative histological diagnosis and
guide patient management.
Methods: We performed a retrospective audit of all MRI-guided biopsies
performed in Leeds patients over a 12-year study period from the initiation
of this service in April 2002. Data collected: indication for MRI; pre-biopsy
MRI score; histology from MRI-guided biopsy and final surgery.
Results: There were 46 MR-guided breast biopsies performed (symptomatic
n = 26, screening n = 20). Indication for MRI was to assess extent of
malignancy (n = 29), an adjunct to triple assessment (n = 11) and a
screening investigation in higher risk patients (n = 6). Pre-biopsy MRI score
was classified as indeterminate MRI 3 (n = 22), suspicious MRI 4 (n = 20) and
malignant MRI 5 (n = 4). In the MRI 3 subgroup, five proved malignant at
MR-guided biopsy with a positive predictive value of 23% (5/22). In the MRI
4/5 subgroup, 14 proved malignant at MR-guided biopsy and a further four
malignant lesions were identified at diagnostic surgical biopsy, with an
overall positive predictive value of 75% (18/24).
Conclusion: MRI-detected lesions are interpreted in clinical context and
attributed an MRI score. If the patient has an increased risk of cancer or
there already is a cancer present, any additional lesion should be regarded
with a higher level of suspicion. MRI 4/5 lesions have a high positive
predictive value for malignancy and should proceed to diagnostic surgical
biopsy if the initial MR-guided biopsy is inconclusive.
P15
PB.22. Does mammographic compression force at breast screening
influence the likelihood of subsequent screening attendance?.
J Meyer1*, A Maxwell2,3, E Harkness2,3, S Astley2,3, C Mercer3, M Wilson3,
M Bydder3, Y Lim3, J Morris4
1University of Manchester Medical School, Manchester, UK.; 2Centre for
Imaging Sciences, Institute of Population Health, University of Manchester,
UK.; 3Nightingale Centre and Genesis Prevention Centre, University Hospital
of South Manchester, Manchester, UK.; 4University Hospital of South
Manchester, Manchester, UK.
Breast Cancer Research 2014, 16(Suppl 1):P15
Introduction: Previous work has demonstrated that approximately 14% of
women who attend their first breast screening appointment fail to attend
the next appointment. It is well recognised that some women experience
marked discomfort or pain during mammography which may be related to
the breast compression force applied. This study investigates whether
applied compression force is related to the likelihood of attendance for the
next scheduled screening mammogram.
Methods: A search on the national breast screening database identified
women aged 46 to 53 who attended for prevalent screening in 2009/10 and
their attendance status at the next invited screen was recorded. A total
of238 subsequent nonattenders were identified together with a sample of
240 women who had subsequently attended that had a similar age
distribution. The compression force used for each of the prevalent screening
images for these 478 women was recorded.
Results: The median age of the women in both groups was 50 years. The
mean compression force applied for all images during the prevalent screen
was 102.1 N for subsequent attenders and 104.4 N for subsequent
nonattenders (P = 0.263). There were similarly no significant differences
between the two groups for maximum compression force (P = 0.410) or
compression force for individual views (LMLO, P = 0.200; RMLO, P = 0.605;
LCC, P = 0.903; RCC, P = 0.246).
Conclusion: No statistically significant relationship has been established
between mammographic compression force and the likelihood of
subsequent screening attendance. Other factors such as compression
pressure (compression force per unit area of contact) may be more
important, and further research is planned to investigate this.
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P16
PB.1. Axillary lymph node ultrasound and needle sampling in
preoperative staging of breast cancer: re-audit.
P Hamilton1*, H Kazi2, L Clarke1, A Robinson1, A Leaver1
1Gateshead Hospitals NHS Trust, Gateshead, UK.; 2South Tyneside Hospitals
NHS Trust, South Tyneside, UK.
Breast Cancer Research 2014, 16(Suppl 1):P16
Introduction: In our unit, invasive breast cancer patients undergo
axillary ultrasound and sometimes needle sampling with fine-needle
aspiration or core biopsy for preoperative staging. Results triage
patients to appropriate axillary surgery. We present a complete audit
cycle. Between cycles 1 and 2, departmental guidelines were changed
to include repeat preoperative biopsy in cases with suspicious
ultrasound but negative biopsy result (LN4 and LN5 of an LN1 to LN5
node ultrasound grading system), and for patients with inconclusive
biopsy results.
Methods: The authors performed a retrospective analysis of
multidisciplinary team meeting records of all invasive breast cancer
patients operated upon from January 2010 to June 2010 (cycle 1), and
from January 2012 to December 2013 (cycle 2). Descriptive statistics were
performed.
Results: Initial audit (cycle 1): 125 female patients with 64% (921/33)
overall combined sensitivity of ultrasound/needle biopsy and 100%
(92/92) specificity. Re-audit (cycle 2): 676 female patients, axillary
ultrasound performed in all cases. Needle sample performed in 52.8%
(357/676) patients. Repeat needle sampling in 16% (57/357) patients:
77.2% (44/57) benign, 22.8% (13/57) malignant. Ultrasound sensitivity
79.1% (163/206), needle sampling sensitivity 76.1% (124/163). Overall
combined sensitivity of ultrasound/needle sampling 59% (466/469).
Overall combined specificity of ultrasound/needle sampling was 99.3%
(466/469).
Conclusion: The introduction of repeat preoperative lymph node biopsy
guidelines did demonstrate node metastases that were not seen on initial
node biopsy, increasing accuracy of triage to an appropriate axillary surgical
procedure in those patients. Unfortunately this did not lead to an
improvement in overall sensitivity of preoperative axillary staging between
cycles.
P17
PB.27. Breast screening with MRI in high-risk women.
D Howarth*, J Gilmour, N Sibal, CE Holmes, N Forester, L McLean
Breast Screening and Assessment Unit, Newcastle, UK.
Breast Cancer Research 2014, 16(Suppl 1):P17
Introduction: This study evaluates the use of annual breast MRI surveillance
for high-risk women, evaluating the recall rate for further imaging, biopsy
and cancer detection rate. We have used breast MRI for surveillance of high-
risk women since 2008.
Methods: High-risk women identified by the Regional Genetic Service
between 2008 and 2013 underwent annual breast MRI (1.5 T), in some cases
in conjunction with digital mammography. This included those with a
genetic predisposition of breast cancer (TP53, BRCA-1, BRCA-2) or equivalent
high risk and previous thoracic radiotherapy. Women were offered MRI
screening between the ages of 20 and 50.
Results: Over 6 years, 184 women underwent 477 screening MRIs. There
were 44 lesions recalled for second-look ultrasound in 39 women. Twenty-
seven lesions had a core biopsy, from which 10 malignant lesions were
identified. Nine of these were invasive ductal carcinoma, of which all were
either grade 2 or 3, varying in size from 4 to 34 mm. One case of ductal
carcinoma in situ was identified. The remaining 17 lesions were benign.
Women who had a normal ultrasound either had an interval MRI after
6 months or were returned to routine yearly screen.
Conclusions: MRI screening of high-risk women is effective, with a cancer
detection rate of 2.1% and a recall rate of 9.2% which are within the
standards set by UK national guidelines. There has been one false
negative screen to date. Breast MRI screening provides a viable
alternative to prophylactic mastectomy for women at high risk of breast
cancer.
P18
PB.2. Axillary node ultrasound in breast cancer: which threshold for
‘diffuse cortical thickening’ predicts node metastasis?.
P Hamilton*, L Clarke, A Leaver
Gateshead Hospitals NHS Trust, Gateshead, UK.
Breast Cancer Research 2014, 16(Suppl 1):P18
Introduction: There is variation in the literature and between breast units
in the diffuse cortical thickening (DCT) threshold used for preoperative
lymph node needle sampling. In our centre, needle sampling is performed
in patients with DCT of 2 mm and above (LN3 of an LN1 to LN5 ultrasound
classification). Results triage patients to appropriate axillary surgery:
sentinel node biopsy or axillary clearance. This study investigates our
2 mm needle sampling threshold, to determine whether we can safely
increase to 2.3 or 3 mm as used in some centres.
Methods: The authors performed a retrospective audit reviewing
multidisciplinary team meeting records and ultrasound images of all
invasive breast cancer patients with LN3 nodes diagnosed and operated
upon in 2012 and 2013. Positive predictive value (PPV) was calculated for
DCT ranges and a post-test probability of a malignant needle sample, and
then a surgical yield of greater than two metastatic nodes.
Results: A total of 223 female patients had an LN3 result and
underwent needle sampling. The PPV for a malignant needle sample for
DCT in the ranges 2.0 to 2.29 mm, 2.3 to 2.99 mm and ≥3.0 mm were
4.1% (1/24), 10.8% (12/111) and 17.4% (15/86). The PPV for a surgical
yield of greater than two metastatic nodes in the ranges 2.0 to 2.29
mm, 2.3 to 2.99 mm and ≥3.0 mm were 16.6% (4/24), 4.5% (5/111) and
9.3%(8/86).
Conclusion: The 2 mm threshold leads to more accurate patient triage
to appropriate axillary surgery, but requires many patients to undergo
needle sampling for a small positive yield. Even the 2 mm DCT
threshold does not identify all patients with bulky (>2 nodes) metastatic
disease.
P19
PB.35. How does semi-automated computer-derived CT measure of
breast density compare with subjective assessments to measure mean
glandular breast density in patients with breast cancer?.
G Bansal*, S Yapa
University Hospital Llandough, Penarth, UK.
Breast Cancer Research 2014, 16(Suppl 1):P19
Introduction: The objectives were to compare radiologists’ breast
mammographic density readings with computed tomography (CT)
subjective measures; and to correlate computer-derived measurement of
CT density with subjective assessments.
Methods: Retrospective review of mammograms and CT scans in 77 breast
cancer patients obtained within 1 year of each other was performed. Two
radiologists independently reviewed both CT and mammograms and
classified each case into four categories as defined by the Breast Imaging,
Reporting and Data system of the American College of Radiology. Inter-
reader agreements were obtained for both mammographic and CT density
subjective evaluations by using the Cohen weighted k statistic. Correlation
was also sought between subjective CT density measurement and
mammographic density measurements for each reader using Spearman
correlation coefficient. The semi-automated computer-derived measurement
of breast density was correlated with visual measurements.
Results: Inter-reader agreements was lower for subjective CT density grades
than for mammographic readings, 0.428 (CI: 0.24 to 0.89) versus 0.571
(CI 0.35 to 0.76), respectively. There was moderately good correlation
between subjective CT density grades and the mammographic density
grades for both readers (0.760, Reader 1; 0.913, Reader 2). The semi-
automated CT density measurement correlated well with the subjective
assessments, with complete agreement of the density grades in 84.9% of
patients and only one-level difference in the rest.
Conclusions: Semi-automated CT density measurements in the evaluation
of breast density correlated well with subjective mammographic density
measurement. Further studies are needed to incorporate this extra
information from a CT scan in the risk stratification of patients.
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P20
PB.7. Large-volume biopsy for B3 lesions without atypia: is once
enough?.
N Forester
Breast Screening and Assessment Unit, Newcastle, UK.
Breast Cancer Research 2014, 16(Suppl 1):P20
Introduction: B3 lesion incidence has increased with digital
mammography and screening of younger women. In January 2012 we
changed management of B3 lesions, following pathways published by
Rajan and colleagues. This study reviews the outcome of vacuum-assisted
biopsy (VAB) in all patients with a B3 diagnosis, comparing initial core
and subsequent VAB for concordance.
Methods: A single-centre, prospective study of all B3 lesions from January
2012 to June 2014 diagnosed by 14G (US) or 7 to 10G (stereotactic) biopsy
with subsequent 7 to 8G VAB.
Results: Over 30 months, 258 B3 lesions were identified in 255 women.
Second-line VAB was performed for 192 lesions (66 no further
intervention/excision biopsy at pathologist request). In total, 79/192
were lesions without atypia (fibroepithelial/papillary/RS/CSL) from which
three were upgraded by VAB (two B5a, one B4). All of the upgraded B3
lesions without atypia had an initial 14G core. In total, 113/192 were
lesions with atypia (ADH/AIDP/FEA/LISN/LCIS/papillary/RS/CSL) from
which 21 were upgraded by VAB (18%). VAB and initial histology were
concordant in 87% of lesions.
Conclusion: VAB in B3 lesions with atypia has a significant and
important upgrade rate to malignancy. However, in the absence of
atypia the upgrade rate is very low (<4%). In this group, there was no
discordant pathology between an initial 10G stereotactic core and
subsequent 7 to 8G large-volume biopsy. To reduce unnecessary
intervention and overdiagnosis, we would like to propose that one 10G
biopsy is sufficient for B3 lesions without atypia, but that lesions
identified on 14G core and those with atypia should continue to have a
second-line VAB performed.
P21
PB.8. Ultrasound-guided excision of fibroadenomas: 9 years’ experience
in a British breast unit.
P Hamilton*, A Sally, CM Lee, A Redman, S Sharma, J Westgarth, A Leaver
Gateshead Hospitals NHS Trust, Gateshead, UK.
Breast Cancer Research 2014, 16(Suppl 1):P21
Introduction: Fibroadenomas are benign breast tumours made up of
glandular and fibrous tissue. Despite their benign pathology, factors such
as size, discomfort, altered breast shape and patient choice sometimes
lead to excision. Traditionally, open excision biopsy has been the method
of choice for fibroadenoma removal but, since 2005, our breast unit has
offered patients minimally invasive ultrasound-guided complete
fibroadenoma excision using vacuum-assisted core biopsy (VACB). We
present an audit of our practice and patient outcomes regarding VACB
excision of fibroadenomas.
Methods: Retrospective audit of all patients that underwent ultrasound-
guided VACB excision of fibroadenoma or fibroadenomata (as defined by
final excision pathology) in our breast unit between January 2005 and June
2014. The authors obtained data from ultrasound images, radiology reports,
pathology records and patient notes. They then performed descriptive
statistics.
Results: Eighty-three female symptomatic patients underwent ultrasound-
guided VACB fibroadenoma excision as an outpatient. Lesions ranged from
7 to 44 mm in the longest axis, and from five to 180 cores were taken. Two
fibroadenomas recurred (2.4%, 2/83): one at 36 months that underwent
further VACB excision and one at 10 months that opted for open surgical
excision. Three patients developed haematoma. Three patients had
incomplete excision noted at the first VACB excision attempt, two of which
were completely removed at a second sitting.
Conclusion: Fibroadenoma excision using ultrasound-guided VACB in an
outpatient setting is an effective alternative to open excision, and is
associated with a low rate of recurrence and morbidity.
P24
PB.23. Breast density in previous screening mammograms of women
with and without breast cancer.
L Sivagnanam1*, A Hufton2, M Berks2, E Harkness2,3, Y Lim2,3, A Maxwell2,3,
M Wilson3, M Bydder3, S Gadde3, DG Evans3,4, A Howell3,4, P Stavrinos3,5,
S Astley2,4
1University of Manchester Medical School, Manchester, UK.; 2Centre for
Imaging Sciences, Institute of Population Health, University of Manchester,
UK.; 3Nightingale Centre and Genesis Prevention Centre, University Hospital
of South Manchester, Manchester, UK.; 4Manchester Breast Centre,
Manchester Cancer Research Centre, University of Manchester, Christie
Hospital, Manchester, UK.; 5The University of Manchester, Manchester
Academic Health Science Centre, University Hospital of South Manchester
NHS Foundation Trust, Manchester, UK.
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Introduction: Increased mammographic density is a well-established risk
factor for breast cancer; much of the evidence is based on semi-
automated or visual assessment of analogue mammograms, although
volumetric measures from digitally acquired mammograms are now
being reported. It is also possible to quantify volumes of fat and gland
from digitised analogue mammograms, given suitable calibration data.
We have measured breast density in cancer cases and controls which had
previous analogue screening mammograms in the PROCAS (Predicting
Risk Of Cancer At Screening) study.
Methods: Forty-nine (44 screen-detected, five interval) cancer cases with
film priors were each matched to one control without cancer on the
basis of age, BMI, menopausal status and current HRT use. The previous
normal screening mammograms for each case were digitised and
volumetric breast density measured in the CC view using a calibrated
step-wedge imaged alongside the breast. Average area-based percent
density was obtained from two readers recording assessments on 10 cm
visual analogue scales (VAS).
Results: Median volumetric percent density was 4.74% (cancer priors) and
4.77% (controls); this was not a significant difference (P = 0.436). For
gland volume the corresponding figures were 37.0 cm3 and 32.1 cm3 (P =
0.667), and for VAS percent density were 28.8% and 27.8% (P = 0.538).
Conclusion: In this sample we did not detect a significant difference
between density in prior mammograms of cancer cases and those of
controls. The sample size, however, was small. Increasing availability of
digital priors of screen-detected cancers will facilitate further exploration
of the ability of increased density to predict the development of cancer.
P25
PB.36. Imaging in gynaecomastia: audit of referral and imaging
practise to establish referral guidelines.
K Bonam*, A Leaver, S Sharma
Gateshead Hospitals NHS Trust, Gateshead, UK.
Breast Cancer Research 2014, 16(Suppl 1):P25
Introduction: There is variation in the literature and between breast units
in use of imaging in clinically suspected gynaecomastia. Our study aim
was to audit referral and imaging in our breast unit, formulating
guidelines and standardising practise.
Methods: The authors performed retrospective data collection of imaging
and pathology for clinically suspected gynaecomastia in our breast unit
between January 2012 and May 2014, using hospital radiology and
pathology computer information systems. Data included clinical history,
clinical score (P1 to P5), ultrasound (U1 to U5) and mammographic scores
(M1 to M5). Patients with clinical suspicion of malignancy (written on
imaging request or P4/P5) were excluded. Descriptive statistics were
performed.
Results: A total of 177 male patients had been referred for imaging with
P1 (19), P2 (113), P3 (11) or no P value (34), clinical history stating or
querying gynaecomastia. Ultrasound was performed on all patients. All P1
and P2 patients were U1 or U2, and M1 or M2 if mammogram was
performed (0/19 P1 patients, 20/113 P2 patients, 4/11 P3 patients). In P1,
P2 and no P value patients, 6/166 patients underwent ultrasound-guided
biopsy (5/6 B2 gynaecomastia, 1/6 B1 benign angiolipoma). In P3
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patients, two biopsies were performed: B2 gynaecomastia in one patient,
but one biopsy (M4U4) revealed B5b invasive carcinoma.
Conclusion: Imaging confirmed the clinical findings in all P1 and P2
patients, but a clinically unsuspected malignancy was diagnosed through
imaging of a P3 patient. The findings support guideline formulation
where imaging is not indicated for typical (P1, P2) gynaecomastia.
Imaging should, however, be performed where there is any doubt at all
about the clinical diagnosis.
P27
PB.10. Stereotactic 20 mm basket Intact Breast Lesion Excision System
biopsy for indeterminate breast microcalcification: pilot study within
a UK breast unit.
A Leaver*, AJ Potterton, S Athey, CM Lee, S Sharma, A Redman, D Hemming,
L Lunt
Queen Elizabeth Hospital NHS Trust, Gateshead, UK.
Breast Cancer Research 2014, 16(Suppl 1):P27
Introduction: For several years our breast unit has evaluated
indeterminate breast microcalcification using stereo-guided vacuum-
assisted core biopsy (VACB) - piecemeal acquisition of unorientated
tissue. The Intact Breast Lesion Excision System (Intact) removes a single
larger piece of tissue, potentially allowing pathologists to calculate
margins and visualise lesion architecture more easily. This study evaluates
the role of the 20 mm Intact in assessment of subcentimetre clusters of
indeterminate breast microcalcification.
Methods: The radiology authors performed the Intact biopsy on
subcentimetre clusters of indeterminate, sonographically invisible breast
microcalcification. A prospective audit was performed, with pathology
information from the multidisciplinary meeting. Technical considerations
encountered during use of the Intact, sample pathology and short-term
patient outcomes are described.
Results: The Intact was performed on 23 female patients, was technically
straightforward to operate and was well tolerated by patients. Metal
fragments from basket removal were radiologically confused with
calcification, but did not result in patient mismanagement.
Pathologists found specimens easier to interpret than VACB samples,
although one (1/23) specimen had a 2.5 mm area of diathermy artefact
that could potentially have obscured a lesion. Three (3/23) cases of ductal
carcinoma in situ (DCIS) were identified, post-biopsy radiographs
consistent with complete excision of microcalcification. The Intact
specimen pathology review showed incomplete excision of disease and
two of the three cases of DCIS had further DCIS on surgical wide local
excision. No invasive disease was identified in any study patient.
Conclusion: In this small pilot study, the Intact has been a reliable and
effective tool for stereotactic diagnostic biopsy of breast microcalcification.
P28
PB.28. Determination of recall rates for assessment in women
undergoing annual surveillance breast MRI: is a rate <10% achievable?.
N Healy*, S Cosgrove, P Wen, T Kwa, F O’Driscoll, G Offiah, Y Roden,
S Sebaoui, K Wolohan, S O’Keeffe
St James Hospital, Dublin, Ireland.
Breast Cancer Research 2014, 16(Suppl 1):P28
Introduction: High recall rates from surveillance breast MRI are associated
with patient anxiety and increased workload. NHSBSP guidelines
recommend a maximum of a 10% recall rate with an expected rate of <7%
in high-risk women undergoing surveillance with breast MRI. Our aims
were to review surveillance breast MRIs performed at our institution from
2009 to 2013 to determine the recall rate and cancer detection rates.
Methods: Surveillance MRIs performed in women at high risk of
developing breast cancer over a 5-year period were reviewed. Breast MRI
was performed using a standard protocol on a 1.5 Tesla MRI. For all
patients with a BIRADS MRI 0, 3, 4 or 5 score, additional imaging, modality
of biopsy and histology were recorded.
Results: A total of 1,119 surveillance breast MRIs were performed over the
5-year period. These included women with a known genetic mutation or
those at high risk based on genetic assessment. In total, 121 (10.8%) had
BIRADS MRI scores which required recall for further imaging. Seventy-one
patients (58.6%) had a biopsy performed and 19 cancers were detected,
giving an overall cancer detection rate of 1.7%. Eleven (9%) were invasive
ductal tumours. Of those recalled, 74 (61%) were in the prevalent round of
screening.
Conclusion: While our data compare favourably with published data, the
breast MRI recall rate is greater than the expected 7% recommended in
the UK. This may be due to large numbers in the prevalent round.
P29
PB.37. Does conventional imaging accurately predict the extent of
disease in women with dense breasts? If so, does this have a
significant impact on patient surgical outcome?.
V Scott*, S Mohammadi, D Tzias, A Wale, S Heller
St George’s Hospital, London, UK.
Breast Cancer Research 2014, 16(Suppl 1):P29
Introduction: Breast density is known to mask disease. This study
evaluated accuracy of conventional imaging in predicting extent of
disease with respect to breast density and surgical outcome.
Methods: Patients treated for biopsy-proven breast cancer between 1
January 2012 and 1 January 2013 were identified. Data regarding patient
demographics and lesion characteristics on imaging and on surgical
pathology were collected. Mammograms were assigned BI-RADS density
scores. Lesion size on imaging was compared with size at final surgical
pathology. Effect of breast density on disease underestimation and on final
surgical outcome was analysed with two-sided Fisher’s exact test.
Results: A total of 237 women were identified; applying exclusion criteria
left a final cohort of 165 patients, median age 62 years (range 24 to
96 years). In total, 114/165 (69%) patients had nondense breasts (BI-RADS
1, 2) and 51/165 (31%) had dense breasts (BI-RADS 3, 4).
Lesion size was underestimated on mammography in 131/165 (79.4%)
patients, compared with 138/165 (83.6%) on ultrasound. Mammography
underestimated disease extent in 42/51 (80.8%) patients with dense
breasts and in 89/114 (78.1%) with nondense breasts (P = 0.6776).
Initially, 97 patients underwent wide local excision, while 68 had
mastectomy. Twenty patients needed further surgery; 17 had re-excision
and three had completion mastectomy. A total 6/51 (11.8%) patients with
dense breasts required further surgery, compared with 14/114 (12.2%)
with nondense breasts (P = 1.0).
Conclusion: Findings show that conventional imaging underestimates
lesion size when compared with final histopathology in dense and
nondense breasts. However, this does not have a significant effect on
surgical outcome.
P30
PB.15. An audit of our benign surgical biopsy rate in the prevalent
round for the reporting year 1 April 2012 to 31 March 2013.
R Geach*, E Kutt, A Valencia
Bristol Royal Infirmary, Bristol, UK.
Breast Cancer Research 2014, 16(Suppl 1):P30
Introduction: The NHSBSP has defined standards with regard to benign
surgical biopsy rates. In the prevalent population, the minimum defined
standard is <3.6/1,000 with a target of <1.8/1,000. At the Avon Breast
Screening Unit we have been identified as outliers.
Methods: We retrospectively reviewed our benign surgical biopsies from
the reporting year 1 April 2012 to 31 March 2013. Thirty-two patients were
identified but only 16 were in the prevalent screening population. For each
patient the following data were collected: mammographic abnormality;
ultrasound abnormality; numerical classification (M1 to M5/U1 to U5
abnormality); lesion size (mm); type of biopsy; B3 histopathological
diagnosis; and final histopathological diagnosis.
Results: Forty-four per cent of lesions biopsied and subsequently
surgically excised were microcalcifications. Seventy-five per cent of the
lesions were M3 indeterminate and were small, 50% measuring <10 mm.
All 16 patients had a B3 pathological diagnosis at biopsy. Forty-four per
cent were AIDP, 12% sclerosing adenosis and a radial scar with the
remainder other B3 diagnoses. Of the 11 patients that had AIDP reported
in the initial biopsy specimen, foci of atypia were present in just four of
these surgical specimens.
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Conclusion: There is inconsistent practice across the UK in the
management of B3 lesions. Some may be referred for surgical excision
whilst other are removed through vacuum-assisted biopsies. We perform
surgical excision for any lesions with atypia. However, to reduce our
benign surgical excision rate we aim to increase the number of
mammotome excisions for B3 lesions without atypia.
P31
PB.19. Distortion conspicuity and cancer detection: a comparison of
cranio-caudal and mediolateral oblique mammographic projections.
S George*, E Muscat, M Sinclair, S Heller
St George’s Healthcare NHS Trust, London, UK.
Breast Cancer Research 2014, 16(Suppl 1):P31
Introduction: Mammographic distortions are an indicator of breast
malignancy. However, whether distortions and their associated cancers are
more readily appreciable on cranio-caudal (CC) or mediolateral oblique
(MLO) projection is unexplored. Our study sought to investigate this in
view of its potential importance for cancer detection.
Methods: A total of 156 mammograms from the South West London
Breast Screening Service were anonymised and randomly ordered. The
series included 79 consecutive studies with confirmed distortion and 77
normal studies. Three blinded readers were asked to establish the
presence of distortion on separately displayed CC and MLO views, and to
score distortion conspicuity (1 to 5). Readers also reported the degree of
confidence (1 to 5) that identified distortions represented malignancy.
Results: Distortion detection sensitivity was 75% for the CC projection and
64% for the MLO projection (P < 0.005) and specificity was 78% for the CC
projection and 84% for MLO (P < 0.05). Cancer detection sensitivity was
86% for the CC projection and 75% for the MLO projection (P = 0.12).
Positive predictive values were 0.14 and 0.11 respectively. Cancer
detection specificity was 55% for the CC projection and 65% for MLO (P <
0.05). Negative predictive values were 0.98 and 0.97 respectively. In cases
of biopsy-proven malignancy, readers were more confident of the
presence of cancer on the CC compared with the MLO view (3.05 ± 0.28
vs. 2.22 ± 0.28; P < 0.05).
Conclusion: The CC projection was associated with significantly higher
distortion detection and higher cancer detection rate than the MLO view.
This view was also associated with greater confidence of identifying
proven malignancy amongst readers.
P32
PB.20. Audit of 5 years of routine screening mammography of the
reconstructed breast.
A Ray*, L McNeilly, A Newland, S Flais
Ealing Hospital, Southall, UK.
Breast Cancer Research 2014, 16(Suppl 1):P32
Introduction: In 2008, allowing for an increase in the number of women
treated with mastectomy and immediate reconstruction, the decision at
our institution was made to carry out mammography of the native and the
reconstructed breast at follow-up. A literature review at that time revealed
that mammography of the reconstructed breast may help diagnose
recurrence before any symptom. This local practice is now audited to
evaluate its impact, and whether it should continue.
Methods: All women who had previously undergone mastectomy and
reconstruction, and were subsequently imaged with mammography
between 2008 and 2013 at Ealing Hospital were included. Subsequent
findings and further investigations have been analysed.
Results: Eighty patients treated with mastectomy and reconstruction had
regular screening mammograms. Ten local recurrences occurred in six
patients. Four recurrences were diagnosed on imaging findings alone
(three on mammography, one on MRI). Six recurrences presented with a
new symptom (palpable lump or skin abnormality). Routine imaging of
the reconstruction generated additional imaging: seven stereobiopsies for
microcalcifications (two recurrences) and two ultrasound scans (one
recurrence). In the same period, 17 ultrasound scans (five recurrences)
and 12 MRIs (one recurrence, but not consistent with the symptom) were
requested for clinical concerns.
Conclusion: Routine imaging of the reconstructed breast can diagnose
local recurrence with limited harm, generating few additional investigations.
However, which patients may benefit and whether this improves outcome is
unclear as the number of cases in our audit is small and the event is
thankfully rare.
P33
PB.39. CT or not CT: a systematic review of the breast on CT of the
chest and abdomen over 1 year - another screening tool?.
S Flais*, A Newland, A Flais, B Ellis
Ealing Hospital, Southall, UK.
Breast Cancer Research 2014, 16(Suppl 1):P33
Introduction: Images of breast tissue are usually included on CT scans of
the chest or abdomen. It is generally thought that CT has a low
sensitivity for breast pathology. We tested this assumption to assess the
importance of the breast as a review area on CT.
Methods: All CT scans which included some breast tissue and were
performed on female patients over a 1-year period at our institution were
retrospectively reviewed by a breast radiologist. The breast tissue was
scrutinised and, if required, an addendum added to the report and sent
urgently to the referring clinician. If the patient was referred for breast
assessment, standard imaging findings were compared with the CT
appearances.
Results: A total of 2,500 CT scans were reviewed. Thirty per cent of the
scans provided imaging of the whole breast. Addendums were added to
112 reports; a recall rate of 5.4%. Sixty-three patients were never referred
for breast imaging. The average time from addendum to assessment was
3 months. Forty-nine patients were assessed with breast imaging.
Twenty-nine patients underwent a biopsy. Eleven patients had a
malignancy. One had a papilloma upgraded to DCIS at surgery.
Conclusion: Significant abnormalities in the breast are visible on CT, and
are frequently overlooked. These results have been fed back to our
general radiology colleagues and there has been a noticeable increase in
reported abnormalities within the breast. We aim to reassess the impact
of this work with further audit, which will hopefully demonstrate a
reduced rate of missed findings in this area.
P34
PB.29. Retrospective correlation between MRI and histopathology in
preoperative assessment of invasive breast carcinoma.
G Gracey*, J McKillen, C Majury, J McAllister
Ulster Hospital, Dundonald, UK.
Breast Cancer Research 2014, 16(Suppl 1):P34
Introduction: Accurate preoperative assessment of a breast tumor has an
important role in the planning of breast cancer treatment. The purpose of
this study was to assess the accuracy of preoperative MRI in sizing breast
tumors of varying pathological subtypes.
Methods: A patient list was populated from the local PACS database. The
sample included all patients with a new diagnosis of breast cancer who
underwent preoperative contrast-enhanced MRI breast imaging over an
18-month period. The MRI breast images were reviewed and the largest
dimension (mm) was recorded. Correlation with the postoperative
pathology report was made.
Results: The sample size included 42 patients with 43 breast cancers.
Average tumor size was 42 mm. There was direct MRI/pathological size
correlation in 41% of cases. MRI overestimated 19% of tumor sizes, and
underestimated 40%. DCIS was under estimated in 40%. MRI accurately
sized 62% of intermediate DCIS compared with 25% high-grade DCIS.
LCIS was underestimated in 31%. MRI accurately sized 45% of invasive
ductal carcinoma and 40% of invasive lobular carcinoma.
Conclusion: This study shows that MRI accurately sizes breast cancer
tumors in 41% of cases, overestimates 19% and underestimates 40%. MRI
is more accurate at measuring intermediate DCIS compared with high-
grade DCIS. A similar accuracy is found between IDC and ILC. Better
preoperative tumor sizing is fundamental for initial surgical planning,
decreasing the need for re-excision or mastectomy and therefore
appropriate treatment.
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P36
PB.43. A clinical audit of breast cancer staging.
A Sulistijo1*, A Falamarzi1, C Chen1, C Lightner Ferrer1, D Tan1, THJ Kong1,
S O’Keeffe2, J Kavanagh2
1School of Medicine, Trinity College Dublin, Ireland.; 2St James’s Hospital,
Dublin, Ireland.
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Introduction: Accurate local and distant staging of breast cancer is
essential in determining appropriate disease management and prognosis.
Staging investigations delay surgical management and increase cost and
manpower requirements. The purpose of the study was to retrospectively
assess the utility of imaging in breast cancer staging at St James’s
Hospital, Dublin between 2012 and 2013.
Methods: The EPR was queried and 559 patients diagnosed with breast
cancer between 2012 and 2013 were selected for inclusion in this study.
The demographic characteristics, radiological (mammogram, US, MRI, CT),
and histopathological records were reviewed. Microsoft Excel 2011 was
used to analyse the data using descriptive statistics.
Results: Of 559 patients (age range 19 to 93 years), 298 patients (53%)
underwent staging CT TAP, triggering at least one further investigation in
134 patients (45%). Forty-three of these staged patients (14%) had distant
metastases; 129 patients (43%) had normal axillary US, of whom five
patients (4%) had distant metastases. In contrast, 22% of patients with
abnormal axillary US had metastases. Five of 32 patients (16%) with
triple-negative disease had metastases. Breast MRI was performed in 30%
of patients, triggering further investigations in 37%. A further 250
investigations were initiated on the basis of CT/MRI in 559 patients.
Conclusion: The excess use of staging CT in patients with early breast
cancer and low axillary lymph node burden was not in compliance with
the local protocol. Patients with triple-negative disease did not have a
higher incidence of metastases at presentation. An average of one further
investigation for every two patients is triggered by staging CT and MRI.
P37
PB.21. Is the technical quality of screening mammograms lower in
Asian women who cannot understand the English language?.
A Steele1*, J Morris1, A Jain1,2, S Iram2, V Reece2, M Griffiths2
1The University of Manchester, UK.; 2The Nightingale Centre and Genesis
Prevention Centre, Manchester, UK.
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Introduction: Good patient and radiographer communication is vital for
good quality mammograms. Many Asian women 47 to 73 years old
cannot understand English. The Radiographers QA Guidelines categorise
mammographic images as Perfect, Good, Moderate and Inadequate
(PGMI). The standards required are 75% PG, 97% PGM and <3% I
(inadequate).
Methods: One hundred women with digital screening mammograms were
randomly selected retrospectively and divided into two groups: Group A,
50 Asian women who could not understand English (confirmed from
radiographer notes on screening forms); Group B, 50 Caucasian women.
Any patients with disability, learning difficulties or previous breast surgery
were excluded. Two folders were created on PACS and images were
anonymised. The films readers were not aware of the classification of the
two groups. All mammograms were independently assessed by two
experienced film-reader advanced practitioners using the PGMI scoring
system. The final score for each case was reached by consensus with a
consultant breast radiologist.
Results: The PGMI mammographic scores for the Asian women are P (0),
G (16), M (26), I (8) and scores for the Caucasian women are P (0), G (31),
M (18), I (1). The mammographic scores of 32% PG, 84% PGM and 16% I
for the Asian women are significantly lower than the scores of 62% PG,
98% PGM and 2% I for the Caucasian women (linear trend test P = 0.001).
Conclusion: The mammographic technical quality appears much lower in
Asian women who cannot understand English, highlighting a need for
improving communication. Further studies are also required to see
whether other factors play any role in the poor technical quality in this
group.
P38
PB.24. How does volumetric breast density change with time?.
J Daniels1*, E Harkness2,3, Y Lim2,3, A Maxwell2,3, J Morris2,4, P Stavrinos3,
M Wilson3, M Bydder3, DG Evans3,5, A Howell3,5
1University of Manchester Medical School, Manchester, UK.; 2Centre for
Imaging Sciences, Institute of Population Health, University of Manchester,
UK.; 3Nightingale Centre and Genesis Prevention Centre, University Hospital
of South Manchester, Manchester, UK.; 4University Hospital of South
Manchester, Manchester, UK.; 5Manchester Breast Centre, Manchester Cancer
Research Centre, University of Manchester, Christie Hospital, Manchester, UK.
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Introduction: Breast density is a well-established independent risk factor
for breast cancer, but risk may also relate to the rate at which breast
density changes over time. Here we aim to establish the baseline rate of
change in volumetric breast density in postmenopausal women
undergoing mammographic screening.
Methods: Data from 3,620 postmenopausal women attending two
consecutive breast screening episodes were obtained from the PROCAS
(Predicting Risk Of Cancer At Screening) study database. Women with
current/previous breast cancer, current HRT users and those without
digital mammographic raw data available were excluded. Volumetric
breast density was obtained from digital mammograms taken at two
consecutive screening episodes using Volpara software. Mean change in
volumetric density was calculated, and its relationship with age, initial
density and parity was assessed.
Results: Mean volumetric breast density decreased from 6.43% at the
initial screen to 5.76% at the subsequent screen, a mean decrease of
0.25% (percentage points) per year (P < 0.001). Fibroglandular volume
showed no significant change, whereas breast volume increased by 30.13
cm3/year (P < 0.001), indicating that the decline in density between
screens was predominantly due to an increase in nondense breast
volume. Decline in breast density was greater with younger age and
nulliparity.
Conclusion: Postmenopausal women undergo a mean decrease in
volumetric breast density of 0.25% (percentage points) per year, largely
due to an increase in nondense breast volume. Establishing a baseline for
volumetric breast density change over time will facilitate further work
into whether variation in this pattern provides additional information in
predicting breast cancer risk.
P39
PB.30. Apparent diffusion coefficient and fractional anisotropy values
as biomarkers for treatment response in breast cancer.
EA Joyce*, AJ Fagan, JP McMorrow, D Byrne, MJ Kennedy, JF Meaney,
SA O’Keeffe
Centre for Advanced Medical Imaging, St James’s Hospital, Dublin, Ireland.
Breast Cancer Research 2014, 16(Suppl 1):P39
Introduction: The aim was to evaluate whether changes in apparent
diffusion coefficient (ADC) and fractional anisotropy (FA) values predict
early response in patients receiving neoadjuvant chemotherapy (NACT)
for breast cancer and to assess the effect of tumour marker clip
placement on ADC values.
Methods: Twenty patients with invasive breast carcinoma underwent
MRI at three time points: at baseline (TP0) and following the first (TP1)
and second (TP2) cycles of NACT. 3T MRI (Achieva; Philips) was
performed using a standard protocol including diffusion-weighted and
diffusion tensor imaging. Baseline and sequential data in responder and
nonresponder groups were compared. To assess the effects of a
commercially available titanium-hydrogel clip on ADC values, DWI was
performed on a phantom consisting of a clip embedded in a tumour-
mimicking target.
Results: At baseline, mean tumour ADC (0.92 × 10-3 mm2/second) was
statistically lower than disease-free fibroglandular breast tissue (1.75 × 10-3
mm2/second) (P < 0.0001). Mean FA values of tumour (FA = 0.139) and
disease-free tissue (FA = 0.135) were similar. Compared with baseline
values, tumour ADC of responders significantly increased at TP1 (P <
0.0001) and TP2 (P < 0.0001) while a significant increase in tumour FA of
responders was seen at TP2 (P < 0.008). No statistical change occurred in
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tumour ADC or FA values of the nonresponder group. The ADC value of
the clip in the phantom (1.7 × 10-3 mm2/second) was higher than the ADC
value of surrounding tumour (1.4 × 10-3 mm2/second).
Conclusion: Changes in ADC and FA values early in the course of
treatment may predict response in patients receiving NACT for breast
cancer. The gel-containing clip used for tumour marking prior to NACT
results in a source of error when calculating tumour ADC values and
should be avoided when drawing regions of interest.
P40
PB.11. Modern management of acute breast abscesses: radiological
interventions replacing surgical incisions?.
N Healy*, M Stenson, S Harte
St James Hospital, Dublin, Ireland.
Breast Cancer Research 2014, 16(Suppl 1):P40
Introduction: Traditionally acute breast abscesses were managed with a
combination of antibiotics and surgical intervention. Despite advances in
imaging techniques and minimally invasive interventions, acute abscesses
remain poorly managed with significant treatment delays. The aim of this
study was to review management of acute breast abscesses in a
symptomatic breast service over 4 years and to develop an updated
algorithm for effective and minimally invasive abscess management.
Methods: From January 2010 to June 2014 all acute abscesses referred to
the radiology service were retrospectively reviewed with attention to patient
demographics, US findings, aetiology, radiological or surgical intervention,
treatment duration and outcome. Total number of ultrasounds (USs),
aspirations and US-guided catheter placements were recorded.
Results: A total of 203 acute abscesses attended with 160 US-guided
aspirations and 43 US-guided catheter placements over 4 years. Patients
required on average 2.3 US and 1.4 aspirations during each acute episode.
Puerperal abscesses accounted for 38 (23%) of the aspiration cases and for
29 (67%) of the catheter cases. The mean abscess size managed with
drainage catheters and aspiration was 4.4 cm and 2.7 cm respectively. Four
(2.2%) patients ultimately required surgical intervention.
Conclusions: Radiological assessment and minimally invasive intervention
is an accessible and effective strategy in the management of acute breast
abscesses. This approach limits more aggressive surgical interventions with
improved patient acceptability. An updated treatment algorithm should be
adopted in all symptomatic breast clinics to ensure timely treatment and
optimise outcome.
P41
PB.31. Occult breast carcinoma: an experience at a single unit.
S Meraj*, C Low, V Gaur, S Muthyala
UHCW NHS Trust, Coventry, UK.
Breast Cancer Research 2014, 16(Suppl 1):P41
Introduction: The breast carcinoma presents rarely as metastases to the
axillary nodes without an obvious breast lesion seen on conventional
imaging such as mammography and US. In this study we looked at the
usefulness of DCE-MRI of the breast in identifying these tumours at a single
institute. In addition we evaluated the use of second-look US and MRI-
guided biopsy.
Methods: A total of 10 patients were identified from our local MR
database who were diagnosed with occult breast cancer between
February 2012 and April 2014. The data were collected from PACS and
the hospital RIS.
Results: All patients presented with axilllary nodes and had a normal
clinical examination of the breast and had normal mammograms. The
majority of these patients (80%) had mixed-density breast parenchyma. In
80% of patients the cancer could be diagnosed on the DCE-MRI of the
breast. The remaining two patients had normal MR examination. The
morphological features of the lesions were nonmass-like enhancement,
spiculate and lobulated masses, ranging in size from 6 to 35 mm. Fifty per
cent of these patients demonstrated type 3 kinetic curves. In 62.5% of
patients with positive MR, the lesion could be identified and biopsied on
the second-look US. In the remaining two cases the tumour was diagnosed
with MRI-guided biopsy. Most patients underwent wire-guided WLE and
ANC. The majority of these cancers (75%) were ductal NST.
Conclusion: Our experience is similar to previously published literature in
that MRI aids in identifying most of the occult cancers.
P42
PB.3. Detection of lymph node metastases in newly diagnosed breast
cancer patients with axillary ultrasonography in combination with the
Memorial Sloan Kettering Cancer Centre normogram as a prediction tool.
CS Low*, S Meraj, M Sreenivas
University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
Breast Cancer Research 2014, 16(Suppl 1):P42
Introduction: Current axillary lymph node assessment criteria by
ultrasonography (US) depends on cortical thickness >3 mm, focal eccentric
cortical thickness and lobulated cortex. Combination with a prediction tool
may define better patient management strategies.
Methods: Newly diagnosed breast cancer patients within a 1-year period
were randomly selected retrospectively. Inclusion criteria include patients
with final histological correlation following resection. The Memorial Sloan
Kettering Cancer Centre breast cancer normogram has been utilised. Axillary
nodal US findings and histological correlation from fine needle aspiration
cytology (FNAC)/core biopsies were obtained.
Results: A total of 70/160 randomly selected patients fulfilled the inclusion
criteria.
In total, 28/70 patients were positive for axillary nodal metastases. A total
15/28 patients underwent FNAC/core biopsy and 11 were positive. In the
remaining 13 patients, nodal metastases were detected by sentinel lymph
node biopsy (SLNB) in 10 patients and initial axillary node clearance (ANC)
in three patients. These 13 patients had a probability range of 26 to 91%
(mean 59%). The overall probability range in all 28 patients is 6 to 97%
(mean 64%). Forty-two patients did not have lymph node metastases. One
patient did not have axillary US assessment. In total, 10/41 patients had
abnormal nodes on US that were negative on FNAC/core biopsy. All 42
patients had surgical lymph node assessment (38 had SLNB, four had
ANC). The overall probability range is 9 to 80% (mean 36%).
Conclusion: The detection of axillary nodal metastases with US remains low
but combination with the normogram prediction tool may be helpful to
determine patients with high probability to have repeated US assessment
and sampling of normal-looking nodes to increase the detection rate.
P43
PB.4. Ultrasound false negative preoperative axillary assessment in
breast cancer patients undergoing sentinel node biopsy.
L Grosvenor*, M Al-Attar, D Lister, G McDonald, S Kaneri, N Hartley,
M Hoosein, L Sundaram, E Denton
Breast Care Centre, Glenfield Hospital, UHL, Leicester, UK.
Breast Cancer Research 2014, 16(Suppl 1):P43
Introduction: Concern was raised by our local pathology unit regarding an
increase in the number of positive sentinel node biopsies (SNB). As an
imaging group we did not have the evidence base to refute the concerns
raised and therefore undertook a 6-month retrospective review of unit
performance.
Methods: Pathology provided a database list of all patients they regarded
as positive SNB (false negative US assessment). The period covered was
6 months (1 November 2012 to 30 April 2013). This was referenced against
all axillary surgeries during the same period.
Results: The pathology database extended to 98 patients. Multiple
duplications were identified and correctly identified preoperative C5
axillae were excluded. A final cohort of 43 positive SNB (false negative
US) assessments were identified from the 266 SNB procedures performed
in the time period. The 13 operators included locums, trainees, multi-
professionals and external consultant staff. All operators had at least one
false negative assessment of the axilla. Positive nodal histology was
reported for 14 cases as micro-metastases or isolated tumour cells (ITC)
and in 29 cases as macro-metastases/extranodal spread or multiple
involved nodes. Eleven per cent of SNBs were considered false negative
US assessments (29/266). Our NPV calculates at 83.8% (43 patients = 223/
266) for all surgical positive axillae and 89% with exclusion of micro-
metastases/ITC.
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Conclusion: No individual performance or unit concern was outside the
published literature ranges. Individual clinical cases of concern were
identified for peer review/clinical governance. Imaging review has led to
consolidation of the working practice and an ongoing prospective audit
with continual review. However, the balance between adequate
assessment, capacity and resource needs defining. How good is good
enough?
P44
PB.40. What happens to the ductal carcinoma in situ in HER2-positive
cancers treated with neoadjuvant chemotherapy and trastuzumab?.
R Millican-Slater*, D Dodwell, K Horgan, M Mcmahon, B Dall, N Sharma
Leeds Teaching Hospital NHS Trust, Leeds, UK.
Breast Cancer Research 2014, 16(Suppl 1):P44
Introduction: There are few data regarding the effect of neoadjuvant
chemotherapy (NACT) and trastuzumab on any ductal carcinoma in situ
(DCIS) associated with the HER2-positive invasive carcinoma. HER2-
positive breast cancers are more likely to achieve a pathological complete
response (defined as absence of invasive tumour in the final excision
specimen allowing for the presence of DCIS). We review our data to see
what happens to HER2-positive DCIS associated with HER2-positive
invasive cancer treated with NACT.
Methods: All cases that were HER2-positive from our local NACT
database were identified from 2010 to 2012. The imaging features, core
biopsy and final histology were documented.
Results: A total 41 of 150 patients that received NACT (anthracycline and
taxane based) were HER2-positive and treated with trastuzumab. In total,
40/41 cases had surgery following neoadjuvant treatment, 24/41 (59%)
cases had calcifications on mammography, and 21/41 (51%) obtained a pCR.
Of the 24 cases with calcification, 14 (44%) had a pCR with 9/14 (29%)
having residual DCIS. Seven of 24 cases had a WLE in which the
calcifications on mammography were unchanged in extent or appearance.
A total 17/41 were without calcification, seven (57%) had a pCR with 2/7
(62%) having residual DCIS that was noncalcified.
Conclusion: pCR is higher in the HER2-positive group compared with the
HER2-negative group (51% vs. 20%). In total, 48% achieved a pCR with no
residual DCIS but 52% still had residual DCIS, suggesting that
trastuzumab may be less effective in treating HER2-positive DCIS.
P45
PB.17. Are patients who have had total body irradiation at similar risk
of breast cancer to those having mantle radiotherapy? A review of
the evidence and suggestions on breast imaging surveillance.
J Muscat1,2*, G Rubin1
1Brighton and Sussex University Hospitals NHS Trust, Brighton, UK.; 2Mater
Dei Hospital, Msida, Malta.
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Introduction: There are an increasing number of total body irradiation
(TBI) survivors. UK haematology and oncology units follow international
guidelines and advise that they should have annual mammography from
age 40.
Methods: A literature review found a single large study published in
Blood in 2008 based on 3,337 women from 83 centres, who had survived
at least 5 years after transplant [1]. The radiation dose was 8 to 16 Grey
distributed homogeneously rather than to the mediastinum in mantle
radiotherapy. Fifty-two women developed breast cancer at a median of
12.5 years after transplantation, and 47 of these had TBI as well as bone
marrow transplant. Their breast cancer incidence was compared with the
standardised incidence.
Results: The study found that: overall breast cancer risk was moderately
increased, by 2.2 (95% CI = 1.7 to 2.9); risk was concentrated in younger
patients, those treated in their teens and twenties; and the standardised
incidence of those presenting after 20 years was also 10-fold that
expected.
Conclusion: There are similarities between the risks of TBI and mantle
radiotherapy, cancers occurring if irradiated when young and cumulative
risk increasing disproportionately with length of follow up. More work
needs to be done comparing the radiation dose to the breast and
relative breast cancer risk of TBI and mantle radiotherapy. If this shows
that the dose and risk are similar, then TBI patients are most likely to
benefit from similar breast imaging follow up.
Reference
1. Freidman DL, Rovo A, et al: Increased risk of breast cancer among
survivors of allogenic hemopoetic cell transplantation. Blood 2008, 11:
P939-P944.
P46
PB.25. Implementation of two new digital mammography technologies
for Breast Test Wales: more or less accurate?.
T Evans*, B Burlton, K Gower-Thomas
Royal Glamorgan Hospital, South Wales, UK.
Breast Cancer Research 2014, 16(Suppl 1):P46
Introduction: The aim of this study is to compare the performance of
Sectra and Hologic digital mammography, two different technologies
introduced to Breast Test Wales in 2012 for breast cancer screening.
Specifically, any variation in findings and whether different types of
cancer - for example, invasive or non-invasive - are better identified by
either system.
Methods: This is a retrospective study of 50,000 consecutive mammograms
starting from 2012 of females aged 50 to 70 carried out in the Breast Test
Wales mobile screening units. All cancers identified in the two arms of the
study were detailed and compared specifically with regards to type (ductal
or lobular), size, grade, invasion and node status. Performance of each
mammography technology with regard to the detection rate of each cancer
type was analysed for any statistically significant difference.
Results: Of 50,000 women screened, 500 cancers were detected with no
significant difference in overall invasive cancer detection, invasive ductal or
invasive lobular detection found between the two screening technologies.
However, Hologic (1.44 per 1,000) was found to have a significantly higher
non-invasive cancer detection rate than Sectra (2.88 per 1,000), P < 0.001.
Conclusion: While Hologic and Sectra have been found to be comparable
in terms of invasive cancer detection, this study shows a difference in the
number of non-invasive cancers they detect. Further study and a decision as
to whether the difference is clinically significant long term are now required.
P47
PB.16. Breast screening mammograms: recall or not to recall. What is
the golden ratio?.
AR Sever1,2*, R Pietrosanu2, J Weeks2, P Mills2
1University of Hacettepe, Ankara, Turkey.; 2Maidstone Hospital, Maidstone, UK.
Breast Cancer Research 2014, 16(Suppl 1):P47
Introduction: The accuracy of prospectively categorised screening
mammograms prior to assessment was evaluated and the individual recall
and cancer detection rates for each category were studied.
Methods: The screening mammograms of women who attended the
National Health Service Breast Screening Program over a period of 5 years
(April 2008-March 2013) were included in the study. The recalled patients’
films were prospectively categorised into one of six groups: patients with
normal mammograms requiring clinical recall; probably benign; probably
benign/suspicious; suspicious; suspicious/malignant; and malignant.
Recalled patients were subsequently assessed with additional
mammographic views, ± ultrasound and/or needle biopsy. The recall and
cancer detection rates of each category were individually calculated.
Results: A total of 86,405 mammograms (17,881 prevalent and 68,524
incident rounds) were read and 4,125 patients were recalled for assessment
(overall recall rate = 4.8%). A total of 721 patients were diagnosed with
cancer (0.8%). The prevalent recall rate was 9.1% (recommended
programme target <7%) and incident recall rate was 3.6% (target <5%).
Conclusion: Mammograms showing minimal signs of cancer that were
categorised as ‘probably benign’ comprised the largest recall group with a
relatively low detection rate (7%). If patient recall was limited to only more
suspicious groups (that is, PB/suspicious and above), the overall recall rate
would have dropped to 1% from 4.8%; however, 28% of the cancers would
have missed. Patient anxiety generated due to false positive recalls and
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the cost of assessment clinics needs to be carefully balanced against a
higher cancer detection rate.
P48
PB.5. Accuracy of axillary nodal staging on MRI of the breasts:
correlation with ultrasound of the axilla and histopathology findings.
M Wilson1*, A Maxwell1,2, S Gadde1, E Hurley1, M Bydder1, E Harkness1,2,
M Ewins3, S Astley1,2, Y Lim1,2
1The Nightingale Centre and Genesis Prevention Centre, University Hospital
of South Manchester, Manchester, UK.; 2Centre for Imaging Sciences,
University of Manchester, UK.; 3University of Manchester Medical School,
Manchester, UK.
Breast Cancer Research 2014, 16(Suppl 1):P48
Introduction: Ultrasound (US) is routinely used for preoperative staging of
the axilla in women with breast cancer but this has limitations with variable
sensitivities published in the literature. Magnetic resonance imaging (MRI) of
the breasts is frequently performed for preoperative staging of the breasts,
and the axilla can be visualised on these scans. The aim of this study is to
assess the accuracy of axillary nodal staging on MRI of the breasts.
Methods: A 4-year retrospective study was performed that included 205
women with breast carcinoma who underwent preoperative staging MRI
of the breasts. Two consultant radiologists reviewed the MRI. The nodes
were assessed for loss of fatty hilum, eccentric cortical thickness and
maximal short axis diameter >10 mm. The findings were recorded on a
proforma and subsequently correlated with the US findings and surgical
histology results.
Results: For the 205 cases, the sensitivity (95% CI) was 55% (48 to 62%)
for MRI and 49% (42 to 56%) for US. The specificity was 88% (84 to 92%)
for MRI and 98% (96 to 100%) for US. The combination of MRI and US
resulted in an increase in sensitivity to 79% (73 to 85%) with a specificity
of 84% (79 to 89%).
Conclusion: There was no statistically significant difference in the
sensitivity and specificity of preoperative axillary nodal staging between
MRI and US. The combination of MRI and US has been shown to have
significantly higher sensitivity. Careful evaluation of the axilla on MRI to
identify the cases for second-look US may increase the accuracy of
preoperative staging of the axilla.
P49
PB.44. Do qualitative patterns of stiffness help differentiate benign
from malignant breast masses of similar stiffness during shear wave
elastography?.
M Elseedawy1*, P Whelehan2,3, S Vinnicombe2,3, D McLean3, K Thomson3,
A Evans2,3
1University of Dundee, UK.; 2Dundee Cancer Centre, Dundee, UK.; 3Ninewells
Hospital, Dundee, UK.
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Introduction: Previous studies assessing qualitative patterns of stiffness
in breast lesions have not matched benign and malignant lesions for
quantitative stiffness. The purpose of this study is to compare the
qualitative patterns of stiffness of benign and malignant lesions matched
for quantitative stiffness.
Methods: A total of 158 consecutive histologically confirmed benign lesions
with a mean stiffness >30 kPa were identified from a prospective database.
Forty-nine cancers with the same distribution of stiffness as the benign
lesions were identified for comparison. The following features were assessed
by two observers; BIRADS score, whether there was stiffness in the lesion,
outside the lesion, Tozaki classification, homogeneity of stiffness, the
presence of a ring sign, stiffness adjacent to the skin or muscle, and the
assessed likelihood of the stiffness being artefactual. Statistical analysis was
carried out using the chi-square test.
Results: Benign and malignant lesions both had a mean stiffness of 73 kPa.
The following features show a significant association with malignancy;
BIRADS classification 4 or 5 (45 (91%) vs. 99 (63%), P < 0.0001), Tozaki
classification 3 and 4 (43 (88%) vs. 85 (54%), P < 0.001), and presence of
a ring sign (40 (82%) vs. 78 (49%), P < 0.001). The following features were
more common in benign lesions; stiffness in the lesion (103 (65%) vs. 17
(35%), P = 0.0002), stiffness adjacent to skin (99 (63%) vs. 19 (39%), P = 0.003)
and stiffness thought to be probably artefact (74 (47%) vs. 5 (10%),
P < 0.0001).
Conclusion: Qualitative features show significant differences in frequency
when comparing benign and malignant masses. Qualitative features
could be used to help classify breast lesions during SWE.
P50
PB.9. Randomised controlled trial of stereotactic 11G vacuum-assisted
core biopsy for diagnosis and management of malignant
microcalcification.
S Bundred1*, A Maxwell1, J Morris1,2, J Harake3, S Whiteside1,2, J Zhou1,
N Bundred1,2
1University Hospital South Manchester, Manchester, UK.; 2University of
Manchester, UK.; 3Royal Bolton NHS Foundation Trust, Bolton, UK.
Breast Cancer Research 2014, 16(Suppl 1):P50
Introduction: Vacuum-assisted biopsy (VAB) may improve accuracy of
diagnosis of malignant microcalcification (MM) compared with 14G core
biopsy (SCNB), thus reducing requirements for further surgical procedures.
Methods: VAB and SCNB were compared in a randomised controlled trial
(1:1) in first-line diagnosis of MM and subsequent surgical outcomes in two
UK breast screening units. Participants gave written informed consent prior
to randomisation. Exclusions included bleeding diathesis or comorbidity
precluding surgery. SCNB was performed by advanced radiography
practitioners and VAB by radiologists. Quality-of-life (QOL) was assessed
using the EORTC QLQ BR-23 questionnaire pre biopsy, 2, 6 and 12 months
post randomisation. Final pathological diagnosis was compared with the
initial biopsy result. A total of 110 participants were required to show a 25%
improvement in diagnosis with VAB compared with SCNB (90% power).
Results: PPV for MM biopsy was 30.2%. Groups were evenly matched for
age and lesion size (75% <15 mm). Eligibility was assessed for 787 cases;
129 women were randomised. Diagnostic accuracy of VAB was 86% and
SCNB was 84%, which precluded any effect on surgical outcomes; 12.5% of
VAB cases (8.7% SCNB) upgraded from DCIS at surgery. Following VAB, 44%
cases required repeat surgery (29% SCNB). VAB took longer (P < 0.001) and
yielded more specimens (12 vs. 8) (P < 0.01). Three VAB (4.7%) procedures
were complicated by severe bleeding. Significant falls in QOL scores for
global health (P < 0.001) and social functioning (P < 0.04) were observed
over time for both groups.
Conclusion: SCNB and VAB were equally accurate in the first-line
diagnosis of malignant microcalcification.
P51
PB.45. Correlation of perilesional tissue stiffness measured by
ultrasound strain elastography with breast density.
A Di Batista1*, R English2, R Sidebottom2, R Adams2, L Winter2, A Noble1,
A Harris1
1Oxford University, Oxford, UK.; 2Oxford University Hospitals NHS Trust,
Oxford, UK.
Breast Cancer Research 2014, 16(Suppl 1):P51
Introduction: Over an 11-month period a series of patients with screen-
detected breast masses were recruited with ethical approval into a BRC-
funded study designed to evaluate the use of ultrasound elastography in
the sizing of early breast cancer. We present results and imaging examples
from 71 patients in whom BIRADS evaluation of breast density is correlated
with elastography findings of the perilesional tissue.
Methods: Ultrasound elastography was performed in addition to the
standard assessment modalities using a Zonare z.one US unit. Elastography
data were post processed and were classified in terms of the strain
characteristics of the perilesional tissue into stiff or not stiff. Standard
mammogram projections were evaluated by two experienced breast
radiologists (RE and RA) for breast density using the BIRADS system of
classification. Intraobserver (RE) and interobserver (RE, RA) consistency was
evaluated. Histological diagnosis subsequently demonstrated invasive
disease in 55 patients and noninvasive in 16 patients.
Results: Intraobserver and interobserver consistency was 83% and 82%
respectively. There was no case exceeding one category of difference. No
correlation was demonstrated between perilesional tissue characteristics
and background breast density. Sixty-two cases were classified as BIRADS 1
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and 2, of whom 38 had perilesional stroma measures as stiff and 24 as not
stiff. Nine cases were classified as BIRADS 3 or 4, of whom five had
perilesional stroma measures as stiff and four as not stiff.
Conclusion: These results suggest that perilesional tissue stiffness is not
closely related to the underlying breast density.
P54
PB.32. Type of breast surgery in patients undergoing neoadjuvant
chemotherapy: role of DCE-MRI.
M Halim*, M Sreenivas
UHCW NHS Trust, Coventry, UK.
Breast Cancer Research 2014, 16(Suppl 1):P54
Introduction: The aim was to assess the role of MRI in neoadjuvant
chemotherapy and whether this has helped the surgical decision. A
secondary aim was to identify the pattern of malignant lesions seen on MRI
and to correlate this with the surgical decision.
Methods: Twenty-seven consecutive patients who had MRI scans prior to
neoadjuvant chemotherapy were identified. Nineteen patients had a
postchemotherapy scan.
The pattern of malignant lesions was identified on the baseline MRI and
divided into five previously described categories (circumscribed (type 1),
nodular (type 2), diffuse (type 3), patchy enhancement (type 4) and septal
spread (type 5)).
Results: Out of the 27 patients, 11 patients had mastectomies and 16
underwent breast-conservation surgery (BCS). From the 19 patients who had
a postchemotherapy MRI, four had complete therapeutic response, 14 had
partial response and one showed disease progression. Of the 27 patients, 14
had circumscribed malignancy with an average size of 39 mm (range = 25
to 60 mm), two had a nodular pattern, four were diffuse, six showed patchy
enhancement and one showed septal spread. Of the 14 patients with
circumscribed malignancy, 13 had BCS and one had mastectomy. All four
patients with diffuse malignancy had mastectomies. Five patients with types
2, 4 and 5 (nine patients in total) MRI patterns had mastectomies.
Conclusion: MRI was helpful in the surgical decision where it showed
either complete or partial therapeutic response in circumscribed
malignancies, thereby avoiding unnecessary mastectomies. In diffuse
malignancies, the decision was invariably mastectomy irrespective of the
response to neoadjuvant chemotherapy.
P55
PB.38. Extent of agreement between radiological and pathological size
and factors affecting completeness of excision in breast-conserving
surgery for invasive breast cancer.
C Newlands*, M Dixon, L Williams
University of Edinburgh/Edinburgh Breast Unit, Edinburgh, UK.
Breast Cancer Research 2014, 16(Suppl 1):P55
Introduction: Completeness of excision is the most important factor
influencing local recurrence for invasive breast cancer. The aim of this
study was to determine whether or not radiological underestimation of
tumour size increased the risk of incomplete excision in patients
undergoing breast-conserving surgery (BCS).
Methods: This was a retrospective study of 311 women diagnosed with
invasive breast cancer and treated with BCS. Data were extracted from
patient notes.
Results: Mean underestimation of tumour size was 11.69 mm for
mammography and 17.18 mm for ultrasonography in the incomplete
excision group. For every 1 mm increase in mammographical and
ultrasonographical underestimation, the risk of incomplete excision rose by
10% and 14% respectively. T stage, maximum tumour diameter, multifocal
disease, an in situ component and mammographical underestimation all
significantly increased the risk of incomplete excision when applied to a
best-fit model. The larger the size of the in situ component, the greater the
risk of both radiological underestimation and incomplete excision.
Conclusion: Underestimation of tumour size by current radiological
techniques increases the risk of incomplete excision in women
undergoing BCS. Better preoperative assessment of tumour size is
required to reduce this risk. Larger, prospective studies are needed to
verify the associations found here.
Cite abstracts in this supplement using the relevant abstract number,
e.g.: Newlands et al.: PB.38. Extent of agreement between radiological
and pathological size and factors affecting completeness of excision in
breast-conserving surgery for invasive breast cancer. Breast Cancer
Research 2014, 16(Suppl 1):P55
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